The results also showed that all of the NF2‐associated meningiomas had CD3‐ and CD8‐positive T lymphocytes (13/13, 100%), which are considered indicators of a good PD‐L1 therapy response, providing a foundation for anti‐PD‐L1 therapy. The gene discussed is NF2; the disease is meningioma.